ArticleJournal of patient-reported outcomes2020
Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life.
Article in Journal of patient-reported outcomes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- An evidence review and gap analysis for obstructive hypertrophic cardiomyopathy.BMC cardiovascular disorders · 2024Pooled it
- Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.Journal of the American College of Cardiology · 2024Trial
- Complication management in hypertrophic cardiomyopathy.Heart failure reviews · 2026Review
- Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Patient-Reported Health Status Analysis up to 78 Weeks in the EXPLORER-CN Study.Cardiology and therapy · 2026Article
- Experiences, Values and Goals of People Living with Obstructive Hypertrophic Cardiomyopathy: Exploratory Patient Interviews.Patient preference and adherence · 2026Article
- Qualitative analysis of experiences, burdens, and needs among patients with hypertrophic cardiomyopathy in Japan.Future cardiology · 2025Observational
- Understanding data visualization techniques in qualitative studies used to develop and validate patient-reported outcome measures: a targeted literature review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Review
- Hypertrophic Cardiomyopathy and Phenocopies: New Therapies for Old Diseases-Current Evidence and Future Perspectives.Journal of clinical medicine · 2025Review
- Treatment patterns, outcomes and healthcare resource utilization of obstructive hypertrophic cardiomyopathy in England.ESC heart failure · 2025Observational
- Efficacy of aficamten in obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis.American heart journal plus : cardiology research and practice · 2025Review
- Prevalence, Patient Characteristics, and Treatment of Patients with Hypertrophic Cardiomyopathy: A Nationwide Payer Database Study.Cardiology and therapy · 2025Article
- An empirical study on the impact of genetics and gender and its consequences in hypertrophic cardiomyopathy.Global cardiology science & practice · 2025Article
- Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy.European heart journal · 2024Article
- The Diagnosis and Treatment of Hypertrophic Cardiomyopathy.Deutsches Arzteblatt international · 2024Review
- Trusting the True Experts Through Patient-Reported Health Status in Hypertrophic Cardiomyopathy.Journal of the American College of Cardiology · 2024Article
- A Machine Learning Approach to Gene Expression in Hypertrophic Cardiomyopathy.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Article
- Genetic therapies for cardiomyopathy: survey of attitudes of the patient community for the CureHeart project.European journal of human genetics : EJHG · 2024Article
- Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration.CPT: pharmacometrics & systems pharmacology · 2024Article
- Exploring Health-Related Quality of Life in Children With Hypertrophic Cardiomyopathy and Relationship to Physical Activity.Journal of the American Heart Association · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertrophic cardiomyopathy (HCM) is a primary myocardial disorder defined by left ventricular hypertrophy that cannot be explained by another cardiac or systemic disease. There is a general lack of knowledge about patients' perspectives on the symptoms and day-to-day limitations they experience as a result of HCM. We therefore sought an in-depth understanding of patients' experiences of obstructive (oHCM) and nonobstructive (nHCM) forms of the disease, including symptoms and their quality of life impacts, and to develop a conceptual model to capture them.
methodsDevelopment of the HCM conceptual model involved a web-based survey to capture patients' insights, a targeted literature review (which included relevant guidelines and patient advocacy websites), one-to-one interviews with clinical experts, and one-to-one qualitative concept elicitation interviews with patients. Key symptoms and their impacts most important to patients' experiences were identified and used to develop a conceptual model of the patient experience with HCM.
resultsThe HCM symptoms reported by patient interviewees (n = 27) were largely consistent with findings from the patient web survey (n = 444), literature review, and interviews with three expert clinicians. The symptoms most commonly reported in patient interviews included tiredness (89%), shortness of breath (89%), shortness of breath with physical activity (89%), and dizziness/light-headedness (89%). Other symptoms commonly reported included chest pain (angina) (70%), chest pain (angina) with physical exertion (70%), and palpitations (fluttering or rapid heartbeat) (81%). The most commonly reported impacts of HCM symptoms on patients' lives included limitations to physical activities (78%), emotional impacts, including feeling anxious or depressed (78%), and impacts on work (63%). Symptoms and impacts were similar for both oHCM and nHCM.
conclusionsA conceptual model was developed, which identifies the core symptoms that patients with oHCM and nHCM reported as most frequent and most important: shortness of breath, palpitations, fatigue/tiredness, dizziness/light-headedness, and chest pain, as well as the impacts those symptoms have on patients' lives. This HCM conceptual model reflecting patients' experiences and perspectives was used in the development of a patient-reported outcomes instrument for use in clinical trials and it may also help inform the clinical management of HCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.